BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.

Current Treatment Options in Oncology
Guilherme Fleury PeriniNelson Hamerschlak

Abstract

At the end of the 1990s, with the advent of imatinib for chronic myeloid leukemia and rituximab for B cell lymphoproliferative diseases with CD20 expression, there was a great conceptual evolution in the treatment of onco-hematological diseases. Researchers from around the world and the pharmaceutical industry began to focus their efforts on the so-called target therapy used alone or associated with classic chemotherapeutic drugs. In chronic lymphocytic leukemia, the development of second-generation anti-CD20 antibodies, biosimilars, PI3K (phosphatidylinositol 3-kinases) inhibitors, BTK (Bruton's tyrosine kinase) inhibitors, and anti-bcl 2 drugs represented mainly by venetoclax brought new, broader, and more effective opportunities in the treatment of this disease. This breakthrough occurred mainly regarding patients with alteration in 17p or mutation of the p53 gene for whom selecting the new drugs that act on B cell signaling (BTK and PI3K inhibitors) in the first line is mandatory. In fit patients with immunoglobulin heavy chain mutation, it is still acceptable to use the chemotherapy regimen with fludarabine, cyclophosphamide, and rituximab (FCR) and, in those who do not fit or are not IgVH-mutated, bendamustine-rituximab r...Continue Reading

References

Sep 5, 2002·Nature Reviews. Cancer·Suzanne Cory, Jerry M Adams
May 20, 2005·Nature·Tilman OltersdorfSaul H Rosenberg
Dec 21, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew W RobertsRod Humerickhouse
Jan 21, 2014·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Sean D SullivanWen-Yi Shau
Dec 8, 2015·The New England Journal of Medicine·Andrew W RobertsJohn F Seymour
Jan 18, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew S DavidsJohn F Gerecitano
May 12, 2017·Future Oncology·Jennifer Crombie, Matthew S Davids
Mar 22, 2018·The New England Journal of Medicine·John F SeymourArnon P Kater
May 2, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephan StilgenbauerWilliam G Wierda
May 12, 2018·Journal of Hematology & Oncology·Guilherme Fleury PeriniNelson Hamerschlak
Jun 14, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matthew S DavidsJohn F Seymour
Dec 7, 2018·The New England Journal of Medicine·Jennifer A WoyachJohn C Byrd
Jun 6, 2019·The New England Journal of Medicine·Kirsten FischerMichael Hallek
Jul 12, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter HillmenTalha Munir
Jul 30, 2020·The New England Journal of Medicine·Jan A Burger
Sep 29, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Arnon P KaterJohn F Seymour

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.